Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion.
Manuel Casselholm de SallesDavid EpsteinPublished in: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2021)
In a clinical setting, a substantial part of patients is still in follow-up a long time after presentation. The visual and anatomical outcomes were better in patients treated with anti-VEGF agents compared to subjects receiving a DEX implant.
Keyphrases
- end stage renal disease
- optical coherence tomography
- diabetic retinopathy
- vascular endothelial growth factor
- endothelial cells
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- low dose
- high dose
- type diabetes
- stem cells
- metabolic syndrome
- bone marrow
- case report
- replacement therapy
- combination therapy
- age related macular degeneration
- chemotherapy induced